A three-dimensional model of the human extracellular Ca 2؉ -sensing receptor (CaSR) has been used to identify specific residues implicated in the recognition of two negative allosteric ). However, our study indicates subtle differences between the binding of these two compounds. Importantly, the observation that some mutations that have no effect on calcimimetics recognition but which affect the binding of calcilytics in TM3 and TM5, suggests that the binding pocket of positive and negative allosteric modulators is partially overlapping but not identical. Our CaSR model should facilitate the development of novel drugs of this important therapeutic target and the identification of the molecular determinants involved in the binding of allosteric modulators of class 3 G-protein-coupled receptors.
1 from bovine parathyroid has shed light on the molecular mechanisms implicated in the regulation of parathyroid hormone (PTH) secretion (1) . The role of CaSR in calcitonin secretion in the thyroid and ion maintenance in the kidney has also been investigated and its presence has been detected in various tissues such as the intestine, the lung, as well as in bone (2) where it has been proposed as a molecular target for the actions of strontium ranelate, a candidate drug for the treatment of female osteoporosis (3, 4) . Its expression in oligodendrocyte cells during development (5, 6) and its presence on nerve terminals suggest additional roles for this receptor (7, 8) .
The CaSR belongs to family 3 of G-protein-coupled receptors (GPCRs) characterized by a long bilobed amino-terminal tail proposed to contain the ligand binding sites. This family includes metabotropic glutamate receptors (mGluRs), ␥-aminobutyric acid, taste, and putative pheromone receptors (9, 10) . Positive allosteric modulators of the CaSR, also called calcimimetics, have been characterized (11) (12) (13) (14) . One of these, NPS R-568, a phenylalkylamine ( Fig. 1) , has been proposed to selectively activate the parathyroid CaSR resulting in an inhibition of PTH secretion both in vitro and in vivo (15) . The therapeutic potential of NPS R-568 and its derivatives has been demonstrated in patients with primary hyperparathyroidism as well as in patients exhibiting secondary hyperparathyroidism linked to renal disease. NPS R-568 has been shown to interact with residues located in the extracellular region delimited by the seven transmembrane domains (TMs) (16 -19) .
The negative allosteric modulator NPS 2143 ( Fig. 1 ) was recently introduced as the first negative allosteric modulator of the CaSR. This compound, also called a calcilytic, inhibits the biological effects elicited by Ca 2ϩ or by a calcimimetic acting on the CaSR but does not affect the responses elicited by the activation of several other GPCRs. When applied to bovine parathyroid cells in culture, NPS 2143 stimulated the secretion of PTH (20) . After in vivo injection of this molecule, a rapid and sustained increase of plasma PTH was observed in the rat, and long term treatment of ovariectomized rats, an animal model of osteoporosis, was followed by a large increase in bone turnover (20, 21) . These data suggest that NPS 2143, and calcilytics in general, might be useful for regulating the plasma PTH level, thereby representing an interesting pharmacological target for drug development. The identification and characterization of calcimimetics and calcilytics as well as their associated molecular mechanisms of action are therefore important goals.
In this report, we have identified the binding site(s) of NPS 2143 in the human CaSR using a three-dimensional model of this receptor based on the x-ray structure of bovine rhodopsin (22) that we have recently reported (23) . Comparison of the ligand binding pocket of both NPS 2143 and Calhex 231 ( Fig.  1) , a structurally different negative allosteric modulator of the CaSR that we have recently characterized (23) , led us to demonstrate that these two calcilytics interact with overlapping binding sites in the TMs. Moreover, we report the calcimimetic properties of (R)-2-[1-(1-naphthyl)ethylaminomethyl]-1H-indole (Calindol) (Fig. 1) , which also belongs to a novel structurally different series of calcimimetics (24) . We have, furthermore, examined if the amino acids involved in the recognition of the calcilytics Calhex 231 and NPS 2143 are also implicated in the binding of the calcimimetics Calindol and NPS R-568.
Our data suggest that calcilytics and calcimimetics interact with several identical residues only within the sixth and seventh TMs. These studies further validate our CaSR model based on the crystal structure of bovine rhodopsin and provide a rational framework for the development of more selective and potent allosteric modulators of the CaSR.
MATERIALS AND METHODS
Preparation of Calindol-Calindol was prepared as its hydrochloride salt. Briefly, indole-2-carboxylic acid in chloroform was treated for 16 h at room temperature with excess thionyl chloride in the presence of catalytic N,N-dimethylformamide. The reaction of the resulting acid chloride with (R)-(ϩ)-1-(1-naphthyl)ethylamine and triethylamine afforded (R)-[1-(1-naphthyl)ethyl]-1H-indole-2-carboxamide. Reduction of the latter with lithium aluminum hydride-aluminum chloride in refluxing tetrahydrofuran for 24 h gave (R)-2-[1-(1-naphthyl)ethylaminomethyl]-1H-indole, i.e. Calindol. Details of the synthesis and structural characterization of Calindol will be published elsewhere. NPS 2143,
2-naphthyl)ethylamine, was prepared as described (25) . NPS R-568, (R)-N-(3-methoxy-␣-phenylethyl)-3-(2-chlorophenyl)-1-propylamine, was synthesized as its hydrochloride salt as described (5) .
Plasmids-The human wild-type (WT) CaSR cDNA (provided by Prof. M. Freichel), and the mutant CaSRs T764A, H766A, F684A, F688A, L776A, W818A, F821A, I841A, E837A, have been reported (23) . R680A mutant was prepared as the other CaSR mutants previously described (23) , using the appropriate oligonucleotides (Eurobio, Les Ulis, France) to convert arginine to alanine (sequences of oligonucleotides are available on request). Sequencing of the resulting mutated DNA was performed as described (23 Automated Docking of NPS 2143-The Surflex docking program (27) was used to automatically dock NPS 2143 to the previously described three-dimensional model of the CaSR (23) . An idealized active site ligand or protomol (28) was first generated from 33 consensus positions (29) supposed to map the TM cavity of most GPCRs. This protomol consists of the preferred locations of various molecular probes (CH 4 , C ϭ O, N-H) that are then used by the docking engine to search for the best three-dimensional morphological similarity between the protomol and the ligand to dock. A proto_thresh value of 0.5 and a proto_bloat value of 0 were used to generate a compact protomol. A TRIPOS mol2file (TRIPOS Associates Inc., St. Louis, MO) of the antagonist, obtained from a two-dimensional sketch as previously reported (29) was docked into the TM cavity using standard parameters of Surflex used in the "whole" docking approach (27) . The best 30 solutions were finally stored in mol2 format.
RESULTS

Hypothesized Binding Mode of NPS 2143-
We have recently developed a model of the human CaSR based on the crystal structure of bovine rhodopsin that has allowed us to delineate the putative TMs of the CaSR (Ref. 23 and Fig. 2 ). We then used this model to dock the novel calcilytic Calhex 231 ( Fig. 1) into a hydrophobic cavity centered on Glu-837 and formed by two pockets (23) . This observation prompted us to use the same 
model to analyze the potential sites of interaction of NPS 2143, a structurally different calcilytic ( Fig. 1 ). Automated docking of NPS 2143 using the recently described Surflex docking engine (27) disclosed a preferred binding mode ( Table I .
The dose-response curves of NPS 2143 for the three mutants F684A,F688A located in TM3, and E837A located in TM7, respectively, were profoundly affected as shown in Fig. 4 , A and B. Thus, NPS 2143 lost its ability to block the Ca 2ϩ -induced IP response in CaSR having the point mutation F684A,F688A (Ͻ30% inhibition by 10 M NPS 2143), as well as E837A (Ͻ20% inhibition by 10 M NPS 2143). These data indicate that these residues play a key role in NPS 2143 recognition. Analysis of the dose-response of the R680A mutant revealed a ϳ12-fold increase of the IC 50 value for NPS 2143 thereby demonstrating that Arg-680, which is located next to the two crucial phenylalanines Phe-684 and Phe-688 in TM3, also participates in the binding of NPS 2143 (Table I) . However, this mutation led to a significant decrease in the IC 50 of Calhex 231 in inhibiting the Ca 2ϩ -induced IP response (IC 50 ϭ 0.12 Ϯ 0.02 M) compared with the WT receptor (IC 50 ϭ 0.39 Ϯ 0.08 M, p Ͻ 0.05) ( Table  I) . Analysis of the dose response of the I841A mutant indicated a ϳ12-fold increase of the IC 50 value for NPS 2143, which demonstrates that Ile-841, located next to Glu-837 in TM7, is also implicated in the binding of NPS 2143. The last mutations studied, T764A and H766A, corresponding to two residues located in the extracellular loop 2 that could potentially block access of compounds to the TM region, as well as L776A located in TM5, and W818A,F821A both located in TM6, did not significantly affect the ability of NPS 2143 to block the Ca 2ϩ -induced IP response in transfected cells (Table I) .
Potency of Calindol-In a recent preliminary report, we described the synthesis and characterization of a novel series of molecules displaying calcimimetic properties toward the rat CaSR (24) . We have now synthesized and investigated the potency of Calindol (Fig. 1) , which belongs to this family of molecules, toward the human CaSR. In the presence of 2 mM Ca 2ϩ , increasing concentrations of Calindol led to a dose-dependent increase of the IP response in transfected cells, which was similar to that obtained with a reference calcimimetic NPS R-568 (11-13), in parallel experiments performed under the same experimental conditions (Fig. 5) . Analysis of the doseresponse curves gave an EC 50 of 0.31 Ϯ 0.05 and 0.50 Ϯ 0.05 M (mean Ϯ S.E., n ϭ 5) for Calindol and NPS R-568, respectively. In the presence of 1 M Calindol or NPS R-568, the concentration-response curve for Ca 2ϩ was significantly left-shifted (EC 50 for Ca 2ϩ ϭ 3.4 Ϯ 0.1 mM; EC 50 for Ca 2ϩ ϩ 1 M Calindol or NPS R-568 ϭ 1.6 Ϯ 0.3 mM) and the maximal responses were significantly increased (Fig. 6, Table II) . These results show that Calindol and NPS R-568 display similar pharmacological properties toward the human CaSR and that both compounds enhance the affinity of Ca 2ϩ for its receptor. These data also suggest that these molecules are allosteric modulators, and possibly interact at the level of the TM for CaSR. We therefore examined whether amino acid residues involved in the recognition of the calcilytics are also implicated in the recognition of these two calcimimetics.
Functional Analysis of Calindol and NPS R-568 for Stimulation of Ca 2ϩ -promoted Increases of IP Response in CaSR
Mutants-CaSRs harboring the F684A, F688A, L776A, W818A, F821A, E837A, and I841A mutants were transiently transfected into HEK293 cells and dose-response curves for Ca 2ϩ ranging from 0.3 to 10 mM alone or in the presence of 1 M Calindol or NPS R-568 were constructed (Fig. 6 , Table II 23 , and have been generated as described under "Materials and Methods" for the Arg-680 mutant, those for NPS 2143 were calculated from experiments similar to those described in the legend to Fig. 4 and are mean Ϯ S.E. from three to ten independent experiments performed in triplicate. Table II ). For example, the mutant receptors bearing the F684A or F688A mutations exhibited a marked decrease of their EC 50 for Ca 2ϩ , being shifted from 5.9 mM for Ca 2ϩ alone to 2-3 mM in the presence of calcimimetics. Interestingly, the mutant receptor bearing the L776A mutation, which shows an increased sensitivity to Ca 2ϩ (EC 50 ϭ 2.2 mM) compared with the WT CaSR (EC 50 ϭ 3.4 mM, Fig. 6 , Table I ) (23) , displayed a further shift to the left of the Ca 2ϩ doseresponse curve in the presence of either calcimimetic (EC 50 ϳ 0.7-0.8 mM). The effect of both calcimimetics (1 M) was investigated on the IP response induced by Ca 2ϩ (3.4 mM) in cells transfected with the mutant receptor harboring the R680A mutation or the WT CaSR. However, the R680A mutation did not affect the Ca 2ϩ responses in the presence of Calindol and NPS R-568 compared with the WT receptor (data not shown).
A substantial reduction in the maximal receptor response to Ca 2ϩ was observed for the I841A mutant in the presence of both calcimimetics (ϳ40%) and a more modest reduction (ϳ10 -20%) was observed only in the presence of Calindol for the E837A and F684A mutants. The W818A mutant displayed a marked increase of the maximal response to Ca 2ϩ (28 -35%) in the presence of both calcimimetics (Fig. 6, Table II ).
DISCUSSION
Negative allosteric modulation has been reported for many GPCRs including mGluRs that are structurally related to the CaSR (9, 10). However, despite the obvious therapeutic interest in identifying such molecules for the CaSR (15) , only a limited number of structurally different positive and negative allosteric CaSR modulators has been described. To date, the phenylalkylamine NPS R-568 and its derivatives such as Cinacalcet (30) belong to the first family of calcimimetics to have been evaluated as candidate drugs. In this study, we have characterized a CaSR positive allosteric modulator, Calindol, which belongs to a novel chemically different family of molecules. Moreover, we have identified and compared the sites of interaction of both Calindol and NPS R-568 with the CaSR. As well, prior to this study, the binding sites of NPS 2143, the first and sole calcilytic whose pharmacokinetic properties had been reported in vitro and in vivo (20, 21) , were not known. We have now characterized several crucial residues involved in its recognition and compared its sites of interaction to those of Calhex 231, a negative allosteric modulator of the CaSR that we have recently described (23) . This work has allowed us to identify the presence of a positive and a negative allosteric binding site located at the level of the transmembrane domains of the CaSR and to demonstrate that these sites are overlapping but not identical. Moreover, we show important differences in the binding of the two families of calcimimetics and calcilytics that should allow the development of compounds of higher selectivity and affinity.
We have recently synthesized Calhex 231 and characterized its antagonist properties toward the human CaSR and proposed a model of its allosteric interaction with the TM region using a series of CaSR mutants (23) . One of the major findings of our present study concerns the identification of five residues Arg-680 3.28 , Phe-684 3.32 , Phe-688 3.36 , Glu-837 7.39 , and Ile-841 7.43 implicated in the recognition of both NPS 2143 and Calhex 231, two structurally different negative allosteric modulators. Moreover, our data allow delineation of ligand binding pockets for both molecules that are largely overlapping, and are located within the bundle formed by the TMs (Fig. 3B) .
The proposed binding mode of NPS 2143 to the TM cavity of the CaSR exhibits similar features to that previously reported for Calhex 231 and clearly defines the TM region as the primary determinant for its sites of interaction with the receptor. Both compounds are primarily anchored through an H-bond assisted salt bridge to a negatively charged amino acid (Glu-837) located in TM7. Two adjacent hydrophobic pockets are used to locate the two aromatic groups of both compounds, with the bulkier naphthalene moiety anchored to the largest (pocket A) of the two subsites (Fig. 3B) . Last, the gem-dimethyl moiety of NPS 2143 mainly overlaps with the cyclohexyl ring of Calhex 231 and faces the aromatic ring of Phe-684. However, despite these similarities, significant differences are observed that may explain the herein described different affinity profile of both compounds for selected CaSR mutants (Table I) . NPS 2143 is proposed to directly H-bond to the Arg-680 side chain as fully supported by the present study that unambiguously demonstrates that R680A mutation unfavorably affects NPS 2143 binding (Table I) . However, the latter amino acid mutation led to a receptor mutant with significantly enhanced Calhex 231 antagonist activity, which is difficult to predict from our model but that we have already observed for L776A and F821A mutants (23) . Furthermore, the naphthalene moiety of Calhex 231 is very close to Trp-818, a residue of TM6 demonstrated to be crucial for binding this compound (23) , whereas the corresponding naphthalene ring of NPS 2143 is more oriented toward the TM3 residues of pocket A (Phe-688, Val-689). Thus, the W818A mutation is much more detrimental to Calhex 231 binding than to that of NPS 2143. Conversely, NPS 2143 is in closer proximity than Calhex 231 to TM3 amino acids (Phe-688, Val-689) explaining the completely abolished binding of NPS 2143 to the F688A CaSR mutant (Table I and Fig. 4A ). Slight differences are also observed in the positioning of the other substituted phenyl ring of both compounds in pocket B (Fig.  3B ) that may explain dissimilar loss of affinity resulting from the Ile-841 mutation (Table I) . Interestingly, the negatively charged Glu-837 side chain presumably interacts with the protonated secondary amine present in both calcilytics that indicates that this residue plays a key role in calcilytic recognition (Fig. 3B) . In agreement with our published model and current data (Figs. 3 and 4 and Table I), Miedlich et al. (19) have recently reported that F668A, a mutation at a residue located in pocket B of our model and proposed to interact with Calhex 231 (23) , as well as R680A, F684A, and E837A mutations, are accompanied by attenuated IP responses to NPS 2143 after transfection of the human CaSR mutants in HEK293 cells.
These data demonstrate that an allosteric binding pocket located within the seven TMs of the CaSR, a member of class 3 GPCRs, can be modeled using the crystal structure of bovine rhodopsin, a member of class 1 GPCRs. Like other members of this class, activation of the CaSR is believed to occur upon ligand binding to sites located within the extracellular domain constituted by its long amino-terminal tail (1, 7) called a Venus flytrap module (31) . The subsequent conformational change that presumably occurs throughout the cysteine-rich region affects the seven TM regions leading to receptor activation. Interestingly, three acidic residues located in the extracellular loop 2 of the CaSR have been demonstrated to maintain an inactive conformation of the seven TM regions, further highlighting the complex processes of CaSR activation (17) . However, the precise molecular mechanisms involved in such activation are not known. The negative allosteric modulators NPS 2143 and Calhex 231 can either block direct contact of the Venus flytrap module with the seven TM region of the receptor that functions as a dimer, or can prevent the switch between the inactive and active conformation of the TM region, thus preventing further rotation of TM6 required for activation of many GPCRs (32). No attempt was made to model the CaSR in its activated form bound to Calindol or NPS R-568, because of the lack of an adequate three-dimensional template (33) . However, our data emphasizes the crucial role of Glu-837 in anchoring NPS R-568, as previously observed (17, 19) , and of Calindol, presumably through a salt bridge with the protonated secondary amine of the two compounds as we previously proposed for the calcilytics. Our study also underscores the role of Ile-841 in anchoring the two calcimimetics as indicated by the lack of Ca 2ϩ potentiation of IP response by both compounds in the mutants. We were also able to demonstrate the non-involvement of Arg-680, Phe-684, and Phe-688 located in TM3, and Leu-776 located in TM5, previously implicated in calcilytics recognition, in anchoring both calcimimetics because we observed a marked leftshift of the dose-response curve to Ca 2ϩ in the presence of 1 M Calindol or NPS R-568 (Table II, Fig. 6 ). A previous report has shown that a F684A mutation exhibits normal activation by Ca 2ϩ and a profound reduction in the maximal response to Ca 2ϩ , but attenuated responses to NPS R-568, both with respect to IP formation and to mobilization of intracellular Ca 2ϩ after transfection of the CaSR mutant in HEK293 cells (19) . However, our data indicate that the F684A mutant displays a reduced affinity for Ca 2ϩ (EC 50 ϭ 5.9 mM) as deduced from dose-response curve analysis of Ca 2ϩ -induced IP formation as well as a decrease in the maximal response to Ca 2ϩ (Table II  and Ref. 23) , and shows a left-shift of the IP response in the presence of both calcimimetics (EC 50 for Ca 2ϩ ϭ 5.9 mM, and EC 50 for Ca 2ϩ ϩ 1 M Calindol or NPS R-568 ϭ 2.5-2.9 mM) (Table II and Fig. 6 ). It should be noted that the apparent affinity of NPS R-568 and also of Calindol, varies with the concentration of extracellular Ca 2ϩ and therefore is directly linked to the EC 50 of Ca 2ϩ for the receptor mutant. The discrepancies between the two studies of R680A might be attributable to differences in experimental conditions and EC 50 determination.
The current data then suggest that some common features previously reported to participate in the activation of class 1 rhodopsin-like receptors might be conserved in the molecular activation of class 3 GPCRs. Hence, the mutation of two residues (Trp-818 and Phe-821), rather conserved among GPCRs and known to lock class 1 GPCRs in an inactive ground state (32) , affects the ability of both calcimimetics to potentiate Ca 2ϩ binding. Whereas NPS R-568 is proposed to mainly interact with Phe-821, Calindol interacts only with Trp-818. Thus, one of these two key residues could be free for inducing, upon binding of one of the latter two compounds, the conformational switch triggering receptor activation.
Hence, the mutation of Trp-818 and Phe-821 in TM6, Glu-837 and Ile-841 in TM7, affecting both calcimimetics and calcilytics recognition, indicates an overlapping binding pocket for both positive and negative allosteric modulators. However, the complete lack of effect of some mutations on calcimimetics binding but which affect the recognition of calcilytics in TM3 and TM5 (despite the proposed involvement of Phe-668 located in TM3 in the binding of NPS R-568 (19)) suggests rather different modes of interaction between these two classes of ligands. Other amino acids are presumably involved in the recognition of calcimimetics. Recently, Ser-688 and Gly-689 in TM4 and Asn-735 in TM5 have been demonstrated to be involved in the binding of LY487379, a selective positive allosteric modulator at human mGluR2 (34) . Interestingly, these residues do not overlap with those implicated in the binding pocket of the noncompetitive mGluR1 receptor antagonist 1-ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-benzo(d)azepin-3-yl)-1,6-dihydropyrimidine-5-carbonitrile (EM-TBPC), which involved multiple residues located in TM5, TM6, and TM7 (35) . In summary, our present study delineates important residues implicated in the recognition of four CaSR allosteric modulators of different chemical structures and should be of substantial help to further map the region of the CaSR, as well as that of other members of class 3 GPCRs, that are critical for modulation by both agonists and antagonists. We can therefore anticipate that our current model of the CaSR should facilitate the development of novel positive and negative allosteric modulators displaying improved affinity and selectivity and acting within the seven TM region of the CaSR, an attractive drug target. 
